康希诺生物前三季度业绩增长:多产品商业化提速,平台化创新打开成长空间

格隆汇
Yesterday
康希诺生物(06185.HK/688185.SH)10月27日发布2026年第三季度报告。报告显示,公司前三季度实现营业收入约8.82亿元,同比增长27.40%;归属于上市公司股东的净利润约1629万元,同比增长12.82%;扣除非经常性损益后归属于上市公司股东的净利润约为-4498万元,亏损同比收窄45.72%。在国内疫苗市场竞争持续加剧的背景下,公司经营表现进一步改善,创新产品商业化与国际业务拓展持续取得进展。 业绩增长背后,是康希诺生物近年来在研发创新、产品布局和商业化体系建设方面的持续积累。随着创新产品陆续进入市场、产品梯队不断丰富,公司正逐步形成多产品协同发展的业务格局。与此同时,依托五大核心技术平台,公司持续推进创新研发与跨领域合作,为长期发展积蓄动能。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10